Home  »  Markets   »  Here is a breakdown of major shareholders in Cytok...

Here is a breakdown of major shareholders in Cytokinetics Incorporated (NASDAQ: CYTK)

Cytokinetics Incorporated (NASDAQ: CYTK) is -18.66% lower on its value in year-to-date trading and has touched a low of $33.10 and a high of $55.80 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CYTK stock was last observed hovering at around $37.76 in the last trading session, with the day’s loss setting it -0.49%.

Currently trading at $37.27, the stock is -9.40% and -12.04% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.77 million and changing -1.30% at the moment leaves the stock -15.97% off its SMA200. CYTK registered -0.61% loss for a year compared to 6-month loss of -31.56%.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


The stock witnessed a -15.04% gain in the last 1 month and extending the period to 3 months gives it a 4.19%, and is -5.02% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.64% over the week and 4.88% over the month.

Cytokinetics Incorporated (CYTK) has around 409 employees, a market worth around $3.67B and $94.60M in sales. Distance from 52-week low is 12.60% and -33.21% from its 52-week high. The company has generated returns on investments over the last 12 months (-69.30%).

Cytokinetics Incorporated (CYTK) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Cytokinetics Incorporated (CYTK) is a “Buy”. 16 analysts offering their recommendations for the stock have an average rating of 1.90, where 1 rate it as a Hold and 2 think it is a “Overweight”. 13 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Cytokinetics Incorporated is expected to release its quarterly report on 05/11/2023.The EPS is expected to shrink by -54.60% this year

Cytokinetics Incorporated (CYTK) Top Institutional Holders

The shares outstanding are 94.72M, and float is at 90.46M with Short Float at 10.51%.

Cytokinetics Incorporated (CYTK) Insider Activity

A total of 50 insider transactions have happened at Cytokinetics Incorporated (CYTK) in the last six months, with sales accounting for 25 and purchases happening 25 times. The most recent transaction is an insider sale by Malik Fady Ibraham, the company’s EVP Research & Development. SEC filings show that Malik Fady Ibraham sold 4,000 shares of the company’s common stock on Mar 09 at a price of $39.10 per share for a total of $0.16 million. Following the sale, the insider now owns 0.17 million shares.

Cytokinetics Incorporated disclosed in a document filed with the SEC on Mar 06 that Blum Robert I (President & CEO) sold a total of 12,500 shares of the company’s common stock. The trade occurred on Mar 06 and was made at $39.94 per share for $0.5 million. Following the transaction, the insider now directly holds 0.37 million shares of the CYTK stock.

Still, SEC filings show that on Feb 21, Wong Robert (VP, Chief Accounting Officer) disposed off 2,234 shares at an average price of $45.21 for $0.1 million. The insider now directly holds 24,789 shares of Cytokinetics Incorporated (CYTK).

Cytokinetics Incorporated (CYTK): Who are the competitors?

The company’s main competitors (and peers) include Eiger BioPharmaceuticals Inc. (EIGR) that is trading -77.61% down over the past 12 months and Ligand Pharmaceuticals Incorporated (LGND) that is 9.51% higher over the same period. Trevena Inc. (TRVN) is -91.66% down on the 1-year trading charts.

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts